Akt Signaling Pathway represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Akt (protein kinase B) is a serine/threonine kinase that plays a central role in cell survival, growth, metabolism, and synaptic plasticity. Akt serves as a critical downstream effector of phosphatidylinositol 3-kinase (PI3K) signaling and is a key mediator of neurotrophin-induced neuronal survival. Three isoforms of Akt exist—Akt1, Akt2, and Akt3—with distinct but overlapping expression patterns and functions in the nervous system.
In the brain, Akt signaling is essential for neuronal development, synaptic plasticity, glucose metabolism, and protection against apoptotic cell death. Dysregulation of Akt signaling has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS), making it a major therapeutic target for neurodegenerative disorders.
- Chromosome: 14q32.33
- Expression: Widely expressed in all tissues; highest in brain, heart, and skeletal muscle
- Primary function: General cell survival and growth; regulates angiogenesis
- Neurological role: Promotes neuronal survival; involved in learning and memory
- Chromosome: 19q13.2
- Expression: Predominantly in insulin-responsive tissues (muscle, liver, fat)
- Primary function: Metabolic regulation, insulin signaling
- Neurological role: Brain insulin signaling; glucose metabolism in neurons
- Chromosome: 1q43-q44
- Expression: Highest in brain and testis
- Primary function: Neuronal development; cognitive function
- Neurological role: Regulates brain size; involved in synaptic plasticity
¶ Structure and Activation Mechanism
¶ Domain Architecture
Akt contains three conserved domains:
- PH Domain (Pleckstrin Homology): N-terminal domain (aa 1-110) that binds phosphatidylinositol (3,4,5)-trisphosphate (PIP3), recruiting Akt to the plasma membrane
- Kinase Domain (aa 111-408): Catalytic domain with an activation loop containing Thr308 (Akt1)
- Hydrophobic Motif (HM): C-terminal regulatory domain containing Ser473
flowchart TD
subgraph Extracellular
INS[Insulin / IGF-1] -->
BDNF[BDNF] -->
NGF[NGF]
end
subgraph Receptor
IR[Insulin Receptor] -->
TRK[TrkB / TrkA]
end
subgraph PI3K Pathway
IRS[IRS-1/2] -->
PI3K[PI3K Class I] -->
PIP2[PIP2] -->
PIP3[PIP3]
end
subgraph Akt Activation
PDK1[PDK1]
mTORC2[mTORC2]
end
subgraph Downstream Effects
GSK3[GSK-3β Inhibition] -->
MTOR[mTORC1 Activation] -->
CREB[CREB Activation] -->
FOXO[FOXO Nuclear Exclusion] -->
BAD[BAD Inactivation]
end
subgraph Neuronal Outcomes
SURVIVAL[Neuronal Survival] -->
SYNAPTIC[Synaptic Plasticity] -->
METABOLISM[Glucose Metabolism] -->
AUTOPHAGY[Autophagy Regulation]
end
INS --> IR
BDNF --> TRK
NGF --> TRK
IR --> IRS
TRK --> IRS
IRS --> PI3K
PI3K --> PIP2
PIP2 --> PIP3
PIP3 --> PDK1
PIP3 --> mTORC2
PDK1 --> GSK3
mTORC2 --> MTOR
GSK3 --> SURVIVAL
MTOR --> SYNAPTIC
MTOR --> METABOLISM
CREB --> SYNAPTIC
FOXO --> SURVIVAL
BAD --> SURVIVAL
SURVIVAL --> AUTOPHAGY
style PIP3 fill:#f9e79f,stroke:#f39c12
style GSK3 fill:#2ecc71,stroke:#27ae60
style MTOR fill:#e74c3c,stroke:#c0392b
- Receptor activation: Insulin, IGF-1, BDNF, or NGF bind to their respective receptors (insulin receptor, TrkB, TrkA)
- PI3K recruitment: Receptor activation recruits PI3K to the membrane
- PIP3 generation: PI3K phosphorylates PIP2 to generate PIP3
- Akt recruitment: Akt's PH domain binds PIP3, localizing it to the membrane
- Thr308 phosphorylation: PDK1 phosphorylates Akt at Thr308
- Ser473 phosphorylation: mTORC2 phosphorylates Akt at Ser473 for full activation
| Regulator |
Mechanism |
Effect |
| PI3K |
Generates PIP3 |
Required for membrane recruitment |
| PDK1 |
Phosphorylates Thr308 |
Essential for activity |
| mTORC2 |
Phosphorylates Ser473 |
Full activation |
| PHLPP1/2 |
Dephosphorylates Ser473 |
Negative regulation |
| PP2A |
Dephosphorylates Thr308 |
Negative regulation |
| Regulator |
Mechanism |
Effect |
| PTEN |
Dephosphorylates PIP3 |
Blocks Akt membrane recruitment |
| PHLPP1/2 |
Dephosphorylates Ser473 |
Inhibits full activation |
| PP2A |
Dephosphorylates Thr308 |
Reduces catalytic activity |
| SGK1 |
Competes for substrate |
Context-dependent |
Akt promotes neuronal survival through multiple mechanisms:
- GSK-3β inhibition: Akt phosphorylates GSK-3β at Ser9, inhibiting its activity. Since GSK-3β is the primary kinase responsible for tau hyperphosphorylation, Akt-mediated inhibition is neuroprotective
- BAD inactivation: Akt phosphorylates BAD at Ser136, preventing it from inhibiting Bcl-xL and allowing mitochondrial outer membrane permeabilization
- FOXO transcription factors: Akt phosphorylates FOXO1/3a, causing their nuclear export and preventing transcription of pro-apoptotic genes
- NF-κB activation: Akt activates IKK, leading to NF-κB nuclear translocation and expression of anti-apoptotic genes
Akt regulates synaptic plasticity through:
- AMPA receptor trafficking: Akt modulates AMPA receptor insertion into the postsynaptic membrane
- mTORC1 activation: Akt activates mTORC1, promoting local protein synthesis at synapses
- CREB activation: Akt phosphorylates and activates CREB, promoting transcription of plasticity-related genes
- Dendritic spine morphology: Akt signaling regulates spine formation and maintenance
In neurons, Akt regulates:
- GLUT3/4 translocation: Akt promotes glucose transporter insertion into the neuronal membrane
- Glycogen synthesis: Akt inhibits glycogen synthase, redirecting glucose to other pathways
- Mitochondrial function: Akt regulates mitochondrial biogenesis and function
Akt signaling is impaired in Alzheimer's disease through multiple mechanisms:
- IRS-1 serine phosphorylation: In AD brain, IRS-1 is phosphorylated at inhibitory serine residues (Ser312, Ser616, Ser636), uncoupling insulin receptors from PI3K/Akt activation
- Aβ interference: Amyloid-beta oligomers compete with insulin for insulin receptor binding and activate inflammatory pathways that suppress Akt signaling
- Reduced Akt phosphorylation: Postmortem AD brain shows decreased Akt phosphorylation at both Thr308 and Ser473
| Deficit |
Molecular Consequence |
Disease Impact |
| Reduced GSK-3β inhibition |
Tau hyperphosphorylation |
Neurofibrillary tangle formation |
| Impaired mTOR signaling |
Synaptic protein synthesis deficits |
Memory impairment |
| Decreased FOXO regulation |
Pro-apoptotic gene expression |
Neuronal death |
| Glucose hypometabolism |
Reduced neuronal energy |
Cognitive decline |
Restoring Akt signaling in AD is a major therapeutic strategy:
- Intranasal insulin: Activates brain insulin receptors and downstream Akt signaling
- GLP-1 receptor agonists: Promote Akt activation through insulin-independent mechanisms
- Akt activators: Direct Akt agonists in development
Akt signaling is critical for dopaminergic neuron survival:
- LRRK2 interactions: G2019S LRRK2 mutations impair Akt signaling, reducing neuronal resilience
- α-synuclein toxicity: Alpha-synuclein oligomers disrupt Akt signaling
- Mitochondrial function: Akt regulates mitochondrial biogenesis and quality control
- GDNF delivery: Promotes TrkB→PI3K→Akt signaling
- Akt pathway modulators: In development for PD
- Mutant huntingtin disrupts IRS-1/PI3K/Akt signaling
- Akt phosphorylation of huntingtin (Ser421) is neuroprotective
- Reduced BDNF signaling impairs Akt activation
- Mutant SOD1 interferes with Akt signaling
- IGF-1 delivery shows neuroprotective effects
| Agent |
Mechanism |
Stage |
Indication |
| Perifosine |
Akt inhibitor |
Preclinical |
Cancer (not neuro) |
| AZD5363 |
Akt inhibitor |
Phase 1 |
Cancer |
| Akti-1/2 |
Akt inhibitors |
Preclinical |
Research tool |
| Agent |
Primary Target |
Effect on Akt |
Status |
| BDNF |
TrkB |
Activation |
Gene therapy trials |
| IGF-1 |
IGF-1R |
Activation |
ALS trials |
| GLP-1 agonists |
GLP-1R |
Activation |
AD/PD trials |
The study of Akt Signaling Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169(3):381-405
-
Gabbouj S et al. Altered insulin signaling in Alzheimer's disease brain — special emphasis on PI3K-Akt pathway. Front Neurosci. 2019;13:629
-
Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol. 2012;4(9):a011189
-
Talbot K et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316-1338
-
Cheng J et al. Akt and autophagy in neurodegenerative disease. Cells. 2022;11(9):1495
-
Zhang L et al. The role of Akt in neuronal survival and degeneration. Front Cell Neurosci. 2023;17:1152347
-
Klein C, Schwarz MJ. Akt signaling in neuronal function and dysfunction. Nat Rev Neurosci. 2024;25(1):23-38
-
Chen Z, Bhatt DK. The role of PI3K signaling pathway in Alzheimer's disease. Front Aging Neurosci. 2024;16:1459025
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
8 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 29%